Since blocking CD40 or CD40L systemically is not suitable for the treatment of ischemic heart diseases because of predicted severe side effects, such as immune suppression, targeting CD40(L) downstream targets and selected CD40 effector cells may be a preferred strategy. Here, CD40LG is linked to coronary artery disorder.